Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the …
Objectives: This study reports a prospectively planned analysis of patients with acute
coronary syndrome who underwent early percutaneous coronary intervention (PCI) in the …
coronary syndrome who underwent early percutaneous coronary intervention (PCI) in the …
[HTML][HTML] Comparison of fondaparinux and enoxaparin in acute coronary syndromes
Fifth Organization to Assess Strategies in … - … England Journal of …, 2006 - Mass Medical Soc
Background The combined use of anticoagulants, antiplatelet agents, and invasive coronary
procedures reduces ischemic coronary events but also increases bleeding in patients with …
procedures reduces ischemic coronary events but also increases bleeding in patients with …
Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra …
Background—Factor Xa plays a central role in the generation of thrombin, making it a novel
target for treatment of arterial thrombosis. Fondaparinux is a synthetic factor Xa inhibitor that …
target for treatment of arterial thrombosis. Fondaparinux is a synthetic factor Xa inhibitor that …
Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results …
Objectives: This study sought to evaluate the relative safety and efficacy of fondaparinux and
enoxaparin in patients with acute coronary syndromes (ACS) treated with glycoprotein (GP) …
enoxaparin in patients with acute coronary syndromes (ACS) treated with glycoprotein (GP) …
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial.
Context Despite many therapeutic advances, mortality in patients with acute ST-segment
elevation myocardial infarction (STEMI) remains high. The role of additional antithrombotic …
elevation myocardial infarction (STEMI) remains high. The role of additional antithrombotic …
Fondaparinux versus Enoxaparin in non–ST-elevation acute coronary syndromes: Short-term cost and long-term cost-effectiveness using data from the Fifth …
MJ Sculpher, G Lozano-Ortega, J Sambrook… - American heart …, 2009 - Elsevier
BACKGROUND: The study aimed to compare the short-term costs and long-term cost-
effectiveness of 2 antithrombotics, fondaparinux and enoxaparin, for non–ST-elevation acute …
effectiveness of 2 antithrombotics, fondaparinux and enoxaparin, for non–ST-elevation acute …
Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non–ST-segment elevation acute coronary syndromes
Background: A recent randomized, controlled trial, the Fifth Organization to Assess
Strategies in Acute Ischemic Syndromes (OASIS 5) trial, reported that major bleeding was 2 …
Strategies in Acute Ischemic Syndromes (OASIS 5) trial, reported that major bleeding was 2 …
Antithrombotic Therapy With Fondaparinux in Relation to Interventional Management Strategy in Patients With ST-and Non–ST-Segment Elevation Acute Coronary …
Background—The Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes
(OASIS 5 and 6) trials evaluated fondaparinux, a synthetic factor Xa inhibitor, in patients with …
(OASIS 5 and 6) trials evaluated fondaparinux, a synthetic factor Xa inhibitor, in patients with …
A dose-finding study of fondaparinux in patients with non–ST-segment elevation acute coronary syndromes: The Pentasaccharide in Unstable Angina (PENTUA) …
ML Simoons, IWG Bobbink, J Boland, M Gardien… - Journal of the American …, 2004 - jacc.org
Objectives: In this dose-finding study, we sought to compare fondaparinux with enoxaparin
in patients with acute coronary syndromes (ACS). Background: Fondaparinux is a synthetic …
in patients with acute coronary syndromes (ACS). Background: Fondaparinux is a synthetic …
Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)–5 trial program evaluating fondaparinux, a …
Michelangelo OASIS 5 Steering Committee - American Heart Journal, 2005 - Elsevier
BACKGROUND: Factor Xa plays a central role in the generation of thrombin, making it a
novel target for treatment of arterial thrombosis. Fondaparinux, a synthetic pentasaccharide …
novel target for treatment of arterial thrombosis. Fondaparinux, a synthetic pentasaccharide …